CRISPR Drug Maker Intellia Therapeutics Sells $108M In IPO Shares
May 6, 2016, 10:06 AM
by
Michael Croft
Xconomy | The latest biopharmaceutical company testing Wall Street's belief in the promise of gene modification has gone public. Intellia Therapeutics sold 6 million shares at $18 each to raise $108 million.
May 06, 2016 | The latest biopharmaceutical company testing Wall Street's belief in the promise of gene modification has gone public. Intellia Therapeutics sold 6 million shares at $18 each to raise $108 million. Xconomy